Competitor Analysis: Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson’s Disease

Publisher: La Merie Publishing
Pages: 32
Format: PDF and Online
Product Line:
Competitor Analysis
Product Code: LMCA0145
Release Date: January of 2015

200.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson’s Disease

The Competitive Intelligence report about Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson’s Disease provides a competitor analysis in the discovery and development pipeline of novel therapeutics for treatment of Parkinson’s Disease (PD). Alpha-synuclein and leucine-rich repeat kinase 2 (LRRK2) represent molecular targets for novel drug candidates to treat PD. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Of the various genetic factors contributing to the pathogenesis of Parkinson’s disease, only mutations in alpha-synuclein and LRRK2 genes cause clinical and neuropathological phenotypes closely resembling the sporadic cases. Therefore, studying the pathophysiological functions of these two PD-related genes is particularly informative in understanding the underlying molecular pathogenic mechanism of the disease. PD-related missense and multiplication mutations in α-synunclein may cause both early- and late-onset PD, whereas various PD-related LRRK2 missense mutations may contribute to the more common late-onset PD.

The report provides a compilation of active projects in research and development for treatment of Parkinson’s disease based on inhibitors of the molecular targets alpha-synuclein and LRRK2 including small molecules, antibodies, vaccines and RNAi. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes
  • Target / Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

 

Competitor Analysis: Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson’s Disease

Table of Contents

  • Alpha Synuclein Inhibitors
  • LRRK2 Inhibitors
  • Corporate R&D Pipelines of alpha Synuclein and LRRK2 Inhibitors



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top